

Richard B Kim

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1508288/richard-b-kim-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

283
papers

25,646
citations

82
h-index

157
g-index

293
ext. papers

27,855
ext. citations

6.7
avg, IF

6.87
L-index

#	Paper	IF	Citations
283	High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor antagonists.. <i>Scientific Reports</i> , 2022 , 12, 1185	4.9	1
282	Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights.. <i>CJC Open</i> , 2022 , 4, 56-64	2	0
281	ORGANIC ANION TRANSPORTING POLYPEPTIDES OATP 2022 , 79-113		
280	Correspondence: Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1*05 Carriage is Associated with Anti-Drug Antibody Formation in Patients with Inflammatory Bowel Disease - Is HLADQA1*05 gone before it's here?. <i>Gastroenterology</i> , 2022 ,	13.3	
279	Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment. <i>Annals of Internal Medicine</i> , 2021 , 174, 432	8	0
278	Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00332	4.2	0
277	Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events. <i>Clinical and Translational Science</i> , 2021 , 14, 1338-1348	4.9	3
276	Pharmacokinetics of a once-daily tacrolimus formulation in first nations and caucasian liver transplant recipients. <i>Transplant International</i> , 2021 , 34, 2266-2273	3	
275	Pharmacogenomic-based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system. <i>Clinical and Translational Science</i> , 2021 , 14, 2231-2241	4.9	1
274	Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates. <i>Frontiers in Pharmacology</i> , 2021 , 12, 713567	5.6	0
273	Association of Baclofen With Falls and Fractures in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2021 , 78, 470-473	7.4	2
272	Mouse NTCP-Mediated Rosuvastatin Uptake In Vitro and in Slc10a1-Deficient Mice. <i>AAPS Journal</i> , 2021 , 23, 17	3.7	1
271	Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-antagonist immunogenicity - does location matter?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1055-1056	6.1	0
270	Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1728-1739	6.9	
269	Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. <i>New England Journal of Medicine</i> , 2020 , 382, 2012-2022	59.2	1616
268	Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 365-372	4.4	1
267	Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn's disease. <i>Scientific Reports</i> , 2020 , 10, 1866	4.9	21

266	In Vitro Functional Characterization and in Silico Prediction of Rare Genetic Variation in the Bile Acid and Drug Transporter, Na-Taurocholate Cotransporting Polypeptide (NTCP,). <i>Molecular Pharmaceutics</i> , 2020 , 17, 1170-1181	5.6	6
265	Near Miss or Standard of Care? Screening for Cancer Patients Receiving Fluorouracil. <i>Current Oncology</i> , 2020 , 28, 94-97	2.8	1
264	Baclofen has a risk of encephalopathy in older adults receiving dialysis. <i>Kidney International</i> , 2020 , 98, 979-988	9.9	6
263	HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 356-363	6.1	22
262	Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. <i>Annals of Internal Medicine</i> , 2020 , 173, 585-587	8	10
261	Genetic variation in the farnesoid X-receptor predicts Crohn's disease severity in female patients. <i>Scientific Reports</i> , 2020 , 10, 11725	4.9	3
260	Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 294-303	5.1	14
259	Letter: immunogenicity of infliximab-ready for routine prediction? Authors' Reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 813-814	6.1	
258	Precision Medicine: Lessons Learned From Implementation of a Pharmacogenetics-Based Patient Care Program in a Real-World Setting. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 933-935	6.1	3
257	Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1. <i>Drug Metabolism and Disposition</i> , 2019 , 47, 832-842	4	22
256	Targeted next generation sequencing as a tool for precision medicine. <i>BMC Medical Genomics</i> , 2019 , 12, 81	3.7	26
255	Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation. <i>Journal of the American Geriatrics Society</i> , 2019 , 67, 1902-1906	5.6	9
254	and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. <i>Pharmaceutics</i> , 2019 , 11,	6.4	32
253	Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1077-1089	6.2	9
252	The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019 , 9,	5.4	31
251	Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression. <i>Molecular Pharmaceutics</i> , 2019 , 16, 4059-4064	5.6	8
250	Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. <i>Oral Oncology</i> , 2019 , 89, 72-78	4.4	16
249	Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 1477-1491	6.1	12

248	Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 485-492	4	12
247	HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 615-620	6.1	37
246	Personalized Anticoagulation: Guided Apixaban Dose Adjustment to Compensate for Pharmacokinetic Abnormalities Related to Short-Bowel Syndrome. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 342.e17-342.e19	3.8	7
245	Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1044-1045	6.1	
244	CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 701-708	4.4	4
243	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 890-899	6.1	113
242	Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 371-379	4.4	5
241	Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 525-533	6.1	8
240	A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. <i>Blood Advances</i> , 2018 , 2, 1935-1945	7.8	17
239	Polymorphism Predisposes to Dopamine Overdose in Parkinson Disease. <i>Frontiers in Neurology</i> , 2018 , 9, 693	4.1	12
238	Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas. <i>Histochemistry and Cell Biology</i> , 2017 , 148, 345-357	2.4	7
237	Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1036-1043	3.8	38
236	CYP3A4 Activity is Markedly Lower in Patients with Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 804-813	4.5	11
235	Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. <i>Molecular Pharmaceutics</i> , 2017 , 14, 310-318	5.6	37
234	Statin therapy: time for a precision medicine approach?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017 , 2, 187-192	1.6	0
233	Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance. <i>Molecular Pharmacology</i> , 2017 , 91, 14-24	4.3	19
232	Genetic Determinants of Clozapine-Induced Metabolic Side Effects. <i>Canadian Journal of Psychiatry</i> , 2017 , 62, 138-149	4.8	24
231	Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 149-156	5.5	16

230	Introduction to Clinical Pharmacology 2017 , 365-388		6
229	Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. <i>Journal of Personalized Medicine</i> , 2017 , 7,	3.6	7
228	Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?. <i>Journal of Clinical Pharmacology</i> , 2016 , 56 Suppl 7, S40-58	2.9	9
227	Home- vs. Laboratory-Based Management Of OSA: An Economic Review. <i>Current Sleep Medicine Reports</i> , 2016 , 2, 107-113	1.2	4
226	Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNF β biologic for ulcerative colitis: a case report. <i>BMC Cancer</i> , 2016 , 16, 304	4.8	7
225	Statin Safety in Chinese: A Population-Based Study of Older Adults. <i>PLoS ONE</i> , 2016 , 11, e0150990	3.7	11
224	Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2016 , 27, 148-54	4.4	44
223	Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016 , 118, 284-91	3.1	18
222	Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. <i>Kidney International</i> , 2016 , 89, 1144-1152	9.9	105
221	A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease. <i>Molecular Pharmacology</i> , 2016 , 90, 437-46	4.3	19
220	Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 325-34	4	45
219	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 3620-30	4	39
218	Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 994-1003	6.1	27
217	SLC transporters as therapeutic targets: emerging opportunities. <i>Nature Reviews Drug Discovery</i> , 2015 , 14, 543-60	64.1	363
216	In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 1646-54	4	9
215	CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 1484-90	4	78
214	Is personalized medicine a dream or a reality?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015 , 52, 1-11	9.4	20
213	Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 428-36	3.2	44

212	Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. <i>Cmaj</i> , 2015 , 187, 174-180	3.5	41
211	The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 167-76	3.8	16
210	OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. <i>British Journal of Cancer</i> , 2015 , 112, 857-65	8.7	51
209	Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 419-28	4.4	19
208	Toward a personalized medicine approach to the management of inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2014 , 109, 994-1004	0.7	37
207	Organic Anion-Transporting Polypeptides 2014 , 43-66		2
206	Personalized medicine: importance of clinical interpretative skills for real-world patient care. <i>Personalized Medicine</i> , 2014 , 11, 395-408	2.2	
205	Emerging from the shadows: a possible link between sleep apnea and cancer. <i>Journal of Clinical Sleep Medicine</i> , 2014 , 10, 363-4	3.1	7
204	Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1268-74	4	101
203	Unintended consequences of therapy in the intensive care unit. <i>JAMA Internal Medicine</i> , 2014 , 174, 574-61.5		
202	Organic cation transporter variation and response to smoking cessation therapies. <i>Nicotine and Tobacco Research</i> , 2014 , 16, 1638-46	4.9	18
201	Solute Carriers. <i>Cancer Drug Discovery and Development</i> , 2014 , 401-442	0.3	
200	Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 367-9	1.9	14
199	Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1647-54 ^{15.4}		26
198	Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 61-9	4.4	28
197	Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1395-9	3.8	3
196	The transfer of pravastatin in the dually perfused human placenta. <i>Placenta</i> , 2013 , 34, 719-21	3.4	26
195	Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 915-9	3.8	9

194	Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 340-5	6.1	18
193	Introduction to Pharmacogenomics of Drug Transporters 2013 , 1-11		1
192	ADME Pharmacogenomics in Drug Development 2013 , 13-37		3
191	Regulatory Perspective on Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 2013 , 39-71		
190	The Pharmacogenomics of Membrane Transporters Project 2013 , 73-108		
189	Emerging New Technology of SNP Typing 2013 , 109-124		
188	OATP1A2, OAT1, and OAT3 2013 , 125-139		1
187	OATP1B1, OATP1B3, and OATP2B1 2013 , 141-169		2
186	OCT (SLC22A) and OCTN Family 2013 , 171-208		5
185	MATE (SLC47) Family 2013 , 209-222		
184	P-glycoprotein (MDR1/ABCB1) 2013 , 271-293		1
183	BSEP (ABCB11) 2013 , 295-309		
182	BCRP (ABCG2) 2013 , 311-343		2
181	MRP2 (ABCC2) and MRP3 (ABCC3) 2013 , 345-364		2
180	MRP4 (ABCC4) 2013 , 365-385		3
179	CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 95-105	4.4	55
178	Pharmacogenetic Advances in Cardiovascular Medicine: Relevance to Personalized Medicine. <i>Current Genetic Medicine Reports</i> , 2013 , 1, 1-14	2.2	2
177	Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. <i>Canadian Journal of Cardiology</i> , 2013 , 29, S24-33	3.8	128

176	Impact of genetic variation in OATP transporters to drug disposition and response. <i>Drug Metabolism and Pharmacokinetics</i> , 2013 , 28, 4-18	2.2	93
175	Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. <i>Circulation: Cardiovascular Genetics</i> , 2013 , 6, 400-8		124
174	Transport function and transcriptional regulation of a liver-enriched human organic anion transporting polypeptide 2B1 transcriptional start site variant. <i>Molecular Pharmacology</i> , 2013 , 83, 1218-28	4.3	22
173	Ciprofloxacin and rifampin have opposite effects on levothyroxine absorption. <i>Thyroid</i> , 2013 , 23, 1374-86.2		14
172	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013 , 112, 164-70	3.1	28
171	Genetic and clinical determinants of CYP3A4 activity in patients using 4βhydroxycholesterol as an in vivo probe. <i>FASEB Journal</i> , 2013 , 27, 672.3	0.9	
170	Regulation of Cytochrome P450 3A4 in Non-Alcoholic Fatty Liver Disease by Fibroblast Growth Factor 21. <i>FASEB Journal</i> , 2013 , 27, lb537	0.9	2
169	Application of a genomics-guided warfarin dosing nomogram for hospitalized patients. <i>FASEB Journal</i> , 2013 , 27, 673.1	0.9	
168	Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. <i>Biochemical Pharmacology</i> , 2012 , 84, 104-12	6	40
167	Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity. <i>Molecular Pharmaceutics</i> , 2012 , 9, 986-95	5.6	18
166	In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 530-42	2.9	25
165	Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 709-22	5.5	2
164	Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. <i>European Heart Journal</i> , 2012 , 33, 2856-2464a	9.5	58
163	Drug transporters in drug efficacy and toxicity. <i>Annual Review of Pharmacology and Toxicology</i> , 2012 , 52, 249-73	17.9	253
162	Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2 ^{-/-} mice and intraindividual variability in human subjects. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 1689-97	2.9	25
161	Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. <i>Blood</i> , 2011 , 118, 3163-71	2.2	72
160	Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2). <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 506-15	1.9	23
159	Functional characterization of genetic variants in the apical sodium-dependent bile acid transporter (ASBT; SLC10A2). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 1740-8	4	18

158	Use of transgenic and knockout mouse models to assess solute carrier transporter function. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 612-6	6.1	13
157	Environmental and genetic factors affecting transport of imatinib by OATP1A2. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 816-20	6.1	48
156	Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis. <i>Hepatology</i> , 2011 , 54, 644-54	11.2	20
155	Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). <i>Drug Metabolism and Disposition</i> , 2011 , 39, 558-62	4	57
154	Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 103-14	1.9	66
153	Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. <i>PLoS ONE</i> , 2011 , 6, e27808	3.7	52
152	Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. <i>British Journal of Pharmacology</i> , 2010 , 161, 1023-33	8.6	5
151	Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , 2010 , 9, 215-36	64.1	2464
150	The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, G248-54	5.1	33
149	Human skeletal muscle drug transporters determine local exposure and toxicity of statins. <i>Circulation Research</i> , 2010 , 106, 297-306	15.7	149
148	Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010 , 25, 553-7	3.9	17
147	Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, F997-F1005	4.3	107
146	Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 45-57	1.9	56
145	Liver X receptor and farnesoid X receptor are major transcriptional regulators of OATP1B1. <i>Hepatology</i> , 2010 , 52, 1797-807	11.2	51
144	Personalized medicine and antiplatelet therapy: ready for prime time?. <i>European Heart Journal</i> , 2009 , 30, 1943-63	9.5	28
143	Blood-brain barrier transporters and response to CNS-active drugs. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 1063-70	2.8	139
142	Identification, expression, and functional characterization of full-length and splice variants of murine organic anion transporting polypeptide 1b2. <i>Molecular Pharmaceutics</i> , 2009 , 6, 1790-7	5.6	16
141	Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. <i>Molecular Pharmaceutics</i> , 2009 , 6, 1644-61	5.6	45

140	The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel. <i>Journal of Cardiovascular Pharmacology</i> , 2009 , 54, 63-71	3.1	29
139	Introduction to Clinical Pharmacology 2009 , 321-338		1
138	Drug Transporters 2009 , 45-84		2
137	Genetic determinants of response to warfarin during initial anticoagulation. <i>New England Journal of Medicine</i> , 2008 , 358, 999-1008	59.2	436
136	Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. <i>Cancer Research</i> , 2008 , 68, 10315-23	10.1	103
135	Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. <i>Cancer Research</i> , 2008 , 68, 9338-47	10.1	102
134	Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. <i>Cancer Research</i> , 2008 , 68, 4983-9	10.1	117
133	A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. <i>Drug Metabolism and Disposition</i> , 2008 , 36, 500-7	4	61
132	Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. <i>Molecular Pharmacology</i> , 2008 , 74, 320-9	4.3	103
131	Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 439-48	1.9	109
130	Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). <i>Drug Metabolism Reviews</i> , 2008 , 40, 317-54	7	86
129	Human MRP2 polymorphisms and their impact on substrate transport. <i>FASEB Journal</i> , 2008 , 22, 1132.4	0.9	
128	Expression and functional characterization of murine organic anion transporting polypeptide 1b2 (oatp1b2/oatp4/lst-1). <i>FASEB Journal</i> , 2008 , 22, 1132.5	0.9	
127	Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 566-78	2.9	283
126	Intestinal drug transporter expression and the impact of grapefruit juice in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 362-70	6.1	334
125	Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 495-502	6.1	211
124	Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 669-78	6.1	118
123	A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. <i>Molecular Endocrinology</i> , 2007 , 21, 1769-80		57

122	Differential inhibition of rat and human Na ⁺ -dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 321, 1170-8	4.7	108
121	Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. <i>Circulation</i> , 2007 , 115, 432-41	16.7	136
120	Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 647-56	1.9	148
119	Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1alpha,25-dihydroxyvitamin D3 via the vitamin D receptor. <i>Molecular Pharmacology</i> , 2006 , 69, 1913-23	4.3	69
118	Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. <i>Clinical Infectious Diseases</i> , 2006 , 42, 401-7	11.6	181
117	Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 318, 1068-75	4.7	84
116	Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. <i>Clinical Infectious Diseases</i> , 2006 , 43, 779-82	11.6	83
115	Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. <i>Clinical Infectious Diseases</i> , 2006 , 43, 783-6	11.6	122
114	The Relevance of Transporters in Determining Drug Disposition 2006 , 423-459		
113	Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 317, 1012-8	4.7	67
112	Transporters and drug discovery: why, when, and how. <i>Molecular Pharmaceutics</i> , 2006 , 3, 26-32	5.6	63
111	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. <i>Gastroenterology</i> , 2006 , 130, 1793-806	13.3	492
110	Inability to upregulate cytochrome P450 4A and 2C causes salt sensitivity in young Sprague-Dawley rats. <i>American Journal of Hypertension</i> , 2006 , 19, 1174-80	2.3	14
109	Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 837-45	1.9	49
108	Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. <i>British Journal of Clinical Pharmacology</i> , 2006 , 62, 485-91	3.8	20
107	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, 186-96	6.1	76
106	OII-B-1. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, P5-P5	6.1	
105	PI-32. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, P15-P15	6.1	1

104	PI-50. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, P20-P20	6.1	2
103	PIII-26. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, P65-P65	6.1	1
102	Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 170-7	6.1	158
101	Polymorphism screening in the cardiac K ⁺ channel gene KCNA5. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 138-44	6.1	37
100	Grapefruit juice ingestion reduces talinolol serum concentration. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, P4-P4	6.1	
99	Grapefruit juice ingestion significantly reduces talinolol bioavailability. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 291-301	6.1	112
98	Effects of infant formula, cow milk and human milk on drug metabolizing enzymes. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, P46-P46	6.1	
97	Multiple OATP transporters mediate the cellular uptake of rosuvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, P64-P64	6.1	4
96	St John's wort-associated drug interactions: short-term inhibition and long-term induction?. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 19-24	6.1	37
95	Transporters and drug therapy: implications for drug disposition and disease. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 260-77	6.1	366
94	Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula. <i>British Journal of Pharmacology</i> , 2005 , 146, 296-305	8.6	18
93	Nuclear receptors and drug disposition gene regulation. <i>Journal of Pharmaceutical Sciences</i> , 2005 , 94, 1169-86	3.9	147
92	Beyond CAR and PXR. <i>Current Drug Metabolism</i> , 2005 , 6, 385-97	3.5	31
91	Hepatic uptake of the novel antifungal agent caspofungin. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 676-82	4	98
90	Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. <i>Journal of Biological Chemistry</i> , 2005 , 280, 9610-7	5.4	266
89	Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. <i>Oncologist</i> , 2005 , 10, 104-11	5.7	98
88	Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. <i>Journal of Infectious Diseases</i> , 2005 , 192, 1931-42	7	210
87	Pharmacogenetics of Drug Transporters. <i>Drugs and the Pharmaceutical Sciences</i> , 2005 , 109-155		

86	Identification of amino acids in rat pregnane X receptor that determine species-specific activation. <i>Molecular Pharmacology</i> , 2004 , 65, 36-44	4.3	73
85	Ethnicity-dependent polymorphism in Na ⁺ -taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. <i>Journal of Biological Chemistry</i> , 2004 , 279, 7213-22	5.4	136
84	P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. <i>Pharmaceutical Research</i> , 2004 , 21, 1294-302	4.5	126
83	Transporters and renal drug elimination. <i>Annual Review of Pharmacology and Toxicology</i> , 2004 , 44, 137-667.9	6.9	188
82	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 13-33	6.1	659
81	Evaluation of ethnicity, gender, and OATP-C genotypes as determinants of pravastatin disposition. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, P66	6.1	
80	A common polymorphism in the adenylyl cyclase type 9 (AC9) gene does not alter vascular responses to isoproterenol. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, P70	6.1	
79	Evaluation of herbal products as potential inhibitors of MDR1. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, P79	6.1	6
78	Identification of nonsynonymous polymorphisms of human organic anion transporting polypeptide-A (OATP-A) associated with altered transport activity. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, P93	6.1	2
77	3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 381-5	6.1	37
76	Alpha 1A-adrenergic receptor polymorphism and vascular response. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 539-45	6.1	18
75	Genetic variability in CYP3A5 and its possible consequences. <i>Pharmacogenomics</i> , 2004 , 5, 243-72	2.6	237
74	Pharmacogenomics of the OATP and OAT families. <i>Pharmacogenomics</i> , 2004 , 5, 273-82	2.6	104
73	Beta2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 517-22		48
72	Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 304, 223-8	4.7	273
71	The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport. <i>Journal of Biological Chemistry</i> , 2003 , 278, 20695-9	5.4	64
70	MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 34, 295-8	3.1	50
69	Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 595-606		217

68	Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 41-50	6.1	184
67	Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 253-63	6.1	146
66	Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. <i>Toxicology and Applied Pharmacology</i> , 2003 , 186, 119-26	4.6	23
65	A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 366-71	6.1	123
64	"Inactive" excipients such as Cremophor can affect in vivo drug disposition. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 394-6	6.1	53
63	Stable and tightly regulated expression of human NA ⁺ taurocholate cotransporting polypeptide (NTCP) using a tetracycline-inducible system. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, P13-P13	6.1	
62	Duration of Grapefruit Juice Effect on Fexofenadine Interaction. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, P48-P48	6.1	2
61	Identification of a new beta1-adrenergic receptor variant VAL5ALA more frequent in African-Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, P97-P97	6.1	
60	Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. <i>European Journal of Clinical Investigation</i> , 2003 , 33 Suppl 2, 1-5	4.6	151
59	Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. <i>British Journal of Pharmacology</i> , 2003 , 139, 1111-8	8.6	75
58	The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. <i>Nature Medicine</i> , 2003 , 9, 220-4	50.5	389
57	CYP2C9 allelic variants: ethnic distribution and functional significance. <i>Advanced Drug Delivery Reviews</i> , 2002 , 54, 1257-70	18.5	285
56	Pharmacogenomics of organic anion-transporting polypeptides (OATP). <i>Advanced Drug Delivery Reviews</i> , 2002 , 54, 1343-52	18.5	92
55	Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances. <i>Advanced Drug Delivery Reviews</i> , 2002 , 54, 1241-2	18.5	12
54	Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2002 , 13, 252-6	2.7	31
53	Transporters and xenobiotic disposition. <i>Toxicology</i> , 2002 , 181-182, 291-7	4.4	67
52	Drugs as P-glycoprotein substrates, inhibitors, and inducers. <i>Drug Metabolism Reviews</i> , 2002 , 34, 47-54	7	297
51	Transport of the sulfated, amidated bile acid, sulfolithocholyllaurine, into rat hepatocytes is mediated by Oatp1 and Oatp2. <i>Hepatology</i> , 2002 , 35, 1031-40	11.2	20

50	Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 71, 11-20	6.1	453
49	Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. <i>Molecular Pharmacology</i> , 2002 , 62, 439-45	4.3	49
48	Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. <i>Anesthesiology</i> , 2002 , 96, 913-20	4.3	185
47	MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 425-7		74
46	Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. <i>Molecular Pharmacology</i> , 2002 , 61, 974-81	4.3	192
45	The anthelmintic agent albendazole does not interact with p-glycoprotein. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 365-9	4	42
44	Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. <i>Molecular Pharmacology</i> , 2002 , 61, 964-73	4.3	167
43	Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 317-23	6.1	24
42	Identification of functionally variant MDR1 alleles among European Americans and African Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 189-99	6.1	773
41	Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. <i>Journal of Biological Chemistry</i> , 2001 , 276, 35669-75	5.4	484
40	Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. <i>Journal of Biological Chemistry</i> , 2001 , 276, 39411-8	5.4	301
39	Site-directed mutagenesis studies on a putative fifth iron ligand of mouse 8S-lipoxygenase: retention of catalytic activity on mutation of serine-558 to asparagine, histidine, or alanine. <i>Archives of Biochemistry and Biophysics</i> , 2001 , 386, 136-42	4.1	8
38	The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. <i>New England Journal of Medicine</i> , 2001 , 345, 1030-5	59.2	309
37	Molecular basis of ethnic differences in drug disposition and response. <i>Annual Review of Pharmacology and Toxicology</i> , 2001 , 41, 815-50	17.9	471
36	Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. <i>Molecular Pharmacology</i> , 2001 , 60, 382-7	4.3	248
35	The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 555-72		269
34	Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 191-7		93
33	In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 809-14		42

32	Human beta2-adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 67, 670-5	6.1	59
31	Drug efflux transporters and antiviral drug therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2000 , 4, 439-446		
30	Identification of amino acid determinants of the positional specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2. <i>Journal of Biological Chemistry</i> , 2000 , 275, 1287-93	5.4	85
29	Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. <i>Molecular Pharmacology</i> , 2000 , 57, 24-35	4.3	86
28	Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. <i>Drug Metabolism and Disposition</i> , 2000 , 28, 655-60	4	277
27	Transporters and drug disposition. <i>Current Opinion in Drug Discovery & Development</i> , 2000 , 3, 94-101		5
26	Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. <i>Circulation</i> , 1999 , 99, 552-7	16.7	376
25	Genetic polymorphism of (S)-mephenytoin 4-hydroxylation in populations of African descent. <i>British Journal of Clinical Pharmacology</i> , 1999 , 48, 402-8	3.8	43
24	Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 66, 224-31	6.1	117
23	Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. <i>Pharmaceutical Research</i> , 1999 , 16, 408-14	4.5	340
22	Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variants. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1999 , 1415, 369-74	3.8	34
21	Allelic, genotypic and phenotypic distributions of S-mephenytoin 4-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 539-550		150
20	β1-Adrenergic receptor polymorphism. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 651-656		44
19	OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. <i>Drug Metabolism and Disposition</i> , 1999 , 27, 866-71	4	445
18	P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. <i>Cancer Research</i> , 1999 , 59, 3944-8	10.1	181
17	Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999 , 291, 1204-9	4.7	73
16	Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 511-6		72
15	Modulation by dietary salt of verapamil disposition in humans. <i>Circulation</i> , 1998 , 98, 2702-8	16.7	28

14	A 12R-lipoxygenase in human skin: mechanistic evidence, molecular cloning, and expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 6744-9	11.5	149
13	The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. <i>Journal of Clinical Investigation</i> , 1998 , 101, 289-94	15.9	812
12	Molecular cloning and functional expression of a phorbol ester-inducible 8S-lipoxygenase from mouse skin. <i>Journal of Biological Chemistry</i> , 1997 , 272, 24410-6	5.4	88
11	High affinity uptake by isolated rat hepatocytes of a linear pseudo-hexapeptide, ditekiren. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1997 , 1328, 41-7	3.8	3
10	Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. <i>British Journal of Clinical Pharmacology</i> , 1997 , 43, 99-103	3.8	4
9	Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. <i>British Journal of Clinical Pharmacology</i> , 1997 , 43, 99-103	3.8	23
8	Characterization of the hepatic canalicular membrane transport of a model oligopeptide: ditekiren. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1997 , 281, 297-303	4.7	11
7	CYP2E1 activity is not altered by influenza vaccination. <i>British Journal of Clinical Pharmacology</i> , 1996 , 42, 529-30	3.8	10
6	In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1996 , 279, 4-11	4.7	56
5	Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 57, 645-55	6.1	132
4	Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 359-67	6.1	168
3	Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. <i>Pharmacogenetics and Genomics</i> , 1994 , 4, 162-5		17
2	Organic Anion Transporting Polypeptides75-104		7
1	Pharmacogenomics of Drug Transporters179-213		4